It Seems Haemonetics Corporation (HAE) Will Go Up. Just Reaches 52-Week High

November 7, 2017 - By Adrian Mccoy

Investors sentiment increased to 1.7 in 2017 Q2. Its up 0.41, from 1.29 in 2017Q1. It is positive, as 18 investors sold Haemonetics Corporation shares while 46 reduced holdings. 37 funds opened positions while 72 raised stakes. 53.69 million shares or 0.37% more from 53.50 million shares in 2017Q1 were reported.
Boston Lc reported 27,645 shares. First Mercantile Trust has 0.07% invested in Haemonetics Corporation (NYSE:HAE). Vanguard Group accumulated 4.74M shares. State Street Corp reported 1.33M shares stake. Principal Financial Inc reported 434,390 shares. Franklin Resource accumulated 1.00M shares or 0.02% of the stock. Connor Clark Lunn Investment holds 0% or 5,225 shares. Aperio Ltd Company holds 10,695 shares. California Pub Employees Retirement has 92,100 shares for 0.01% of their portfolio. New Jersey-based Prudential Financial has invested 0.01% in Haemonetics Corporation (NYSE:HAE). Texas-based Wfg Advisors Ltd Partnership has invested 0% in Haemonetics Corporation (NYSE:HAE). Gemmer Asset Mgmt Lc holds 105 shares. Ahl Llp has invested 0.15% in Haemonetics Corporation (NYSE:HAE). Bnp Paribas Asset Mngmt invested in 0.02% or 59,700 shares. 4.30M are held by Wellington Management Gp Limited Liability Partnership.

Since May 11, 2017, it had 0 buys, and 3 selling transactions for $1.39 million activity. On Monday, May 15 KROLL MARK W sold $355,982 worth of Haemonetics Corporation (NYSE:HAE) or 8,580 shares. On Thursday, May 11 FOOTE SUSAN BARTLETT sold $639,819 worth of Haemonetics Corporation (NYSE:HAE) or 15,314 shares.

The stock of Haemonetics Corporation (NYSE:HAE) hit a new 52-week high and has $55.69 target or 9.00 % above today’s $51.09 share price. The 8 months bullish chart indicates low risk for the $2.69B company. The 1-year high was reported on Nov, 7 by Barchart.com. If the $55.69 price target is reached, the company will be worth $242.10 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 561,046 shares traded or 62.97% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 45.56% since November 7, 2016 and is uptrending. It has outperformed by 28.86% the S&P500.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 9 analysts covering Haemonetics Corporation (NYSE:HAE), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Haemonetics Corporation had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was downgraded by Barrington Research to “Mkt Perform” on Tuesday, February 7. As per Monday, May 16, the company rating was upgraded by Goldman Sachs. Benchmark maintained the stock with “Hold” rating in Wednesday, May 11 report. On Thursday, July 13 the stock rating was upgraded by JMP Securities to “Market Outperform”. The stock has “Outperform” rating by Barrington Research on Tuesday, August 8. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 6. The rating was maintained by Benchmark on Thursday, November 5 with “Hold”. The company was maintained on Thursday, August 31 by Jefferies. As per Tuesday, July 28, the company rating was upgraded by Barrington Research. The firm earned “Market Perform” rating on Tuesday, September 20 by CJS Securities.

More news for Haemonetics Corporation (NYSE:HAE) were recently published by: Prnewswire.com, which released: “Robert E. Abernathy Joins Haemonetics Board of Directors” on October 18, 2017. Prnewswire.com‘s article titled: “Haemonetics Sets Date for Publishing 2nd Quarter and 1st Half Fiscal 2018 …” and published on October 10, 2017 is yet another important article.

Haemonetics Corporation is a healthcare company. The company has market cap of $2.69 billion. The Firm provides various products to clients involved in the processing, handling and analysis of blood. It has a 667.76 P/E ratio. The Company’s divisions include Japan, EMEA, North America Plasma and All Other.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.